Skip to main content
. 2017 Dec 14;103(2):256–265. doi: 10.3324/haematol.2017.178251

Figure 3.

Figure 3.

Graft-versus-host disease and relapse-free survival (GRFS) per disease status (first complete remission (CR1), second remission (CR2) and active disease (Active D)). The 2-year probability of GRFS was 41.7% (95% CI: 34.3–49.2) in CR1 patients, 18.1% (95% CI: 3.6–32.6) in CR2 patients and 2.4% (95% CI: 0–7.2) in Active D patients.